Overview

Study of AMDX-2011P in Subjects With CAA

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with cerebral amyloid angiopathy (CAA).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Amydis Inc.

Collaborator:

National Institutes of Health (NIH)